Phase 1 N=6 A Study in Healthy Men to Find Out How BI 425809 is Taken up and Handled by the Body
Healthy
Primary: Mass Balance Recovery of Total [14C]-Radioactivity in Urine (Feurine, 0-t2) — 48.1 Percentage of dose excreted (%)
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=19 Implications of Fecal Microbiota Transplantation in Modulating the Effects of Liver Cirrhosis
Liver Cirrhosis
Primary: Liver Stiffness by Transient Elastography (FibroScan) — 22.6; 23 kPa
N/A N=25 Sensory Testing of Multiple Forms of Spinal Cord Stimulation for Pain
Chronic Pain · Failed Back Surgery Syndrome · Complex Regional Pain Syndromes
Primary: Spinal Cord Stimulation (SCS)-Induced Changes in Temporal Summation (TS) — 3.67; 3.33; 3.67; 3.33 score on a scale — p=0.2375
Phase 2 N=31 A Study to Investigate the Efficacy, Safety, and Tolerability of DFV890 and MAS825 for Inflammatory Marker Reduction in Adult Participants With Coronary Heart Disease and Clonal Hematopoiesis of Indeterminate Potential (CHIP)
Coronary Heart Disease · Clonal Hematopoiesis of Indeterminate Potential (CHIP)
Primary: Ratio to Baseline Serum Levels of IL-6 for DFV890 Based on an Emax Model — 0.8602; 0.7558; 0.7002; 0.6657 ratio serum levels of IL-6 — p=0.0817
Phase 2 N=22 DaxibotulinumtoxinA Injection for Treatment of Adductor Spasmodic Dysphonia
Adductor Spasmodic Dysphonia · Voice Disorders · Spasmodic Dysphonia
Primary: Our Primary Outcome is the Difference in VHI-10 Score at 30 Days After Injection With DAXI. — 17.81 units on a scale — p=<0.001
Phase 2 N=43 Persica 002 Phase 1b PP353 vs Placebo in the Treatment of Low Back Pain
Chronic Low-back Pain
Primary: Incidence of Adverse Events — 3; 15; 18 Participants
Phase 2 N=36 Study of Capmatinib in Chinese Adult Patients With Advanced Non-small Cell Lung Cancer Harboring MET Exon 14 Skipping Mutation
Non-Small Cell Lung Cancer (NSCLC)
Primary: Overall Response Rate (ORR) Per RECIST v1.1 by BIRC Assessment — 53.3; 38.1 percentage of participants
Phase 1 N=48 Safety, Tolerability and Pharmacokinetics of Benfo-Oxythiamine (B-OT) in Healthy Volunteers
Healthy Volunteers
Primary: Number of Participants With Treatment-Emergent Adverse Events (TEAEs) — 1; 0; 0; 0 Participants
Early Phase 1 N=30 Inhibition of Oral Tumorigenesis by Antitumor B
Squamous Cell Cancer of the Oral Cavity
Primary: Percent of Ki-67 Positive Cells — .4023; .5872; .3732; .5035 percentage of stained tumor cell nuclei
Phase 3 N=195 Study to Describe the Safety, Tolerability, Immunogenicity, and Efficacy of RNA Vaccine Candidates Against COVID-19 in Healthy Individuals
SARS-CoV-2 Infection · COVID-19
Primary: Percentage of Participants With Local Reactions Within 7 Days After Dose 1: Phase 1 — 0; 0; 8.3; 0 Percentage of participants
Phase 2 N=42 Investigation of the NMDA Antagonist Ketamine as a Treatment for Tinnitus
Tinnitus
Primary: GABA and Glutamate (Glx) Levels in the Auditory Cortex Derived From 3T Magnetic Resonance Spectroscopy — 2.11; 2.12; 2.09; 2.03 Ratio — p=0.05
N/A N=239 Educational Intervention in Increasing Knowledge About Prostate Cancer in High-Risk Neighborhoods
Prostate
Primary: Change in Prostate Cancer Knowledge as Measured by the Decisional Conflict Scale — 80; 70 score on a scale
N/A N=1,095 Adolescent Wellness Visits in Tanzania
HIV Testing · Contraceptive Usage
Primary: Number of Adolescents Who Self-reported HIV Testing and Counseling, Inclusive of the Adolescent Wellness Visit — 234; 86 Participants
N/A N=27 Comparison of Non-Invasive Respiratory Monitoring System (RMS)
Respiratory Monitoring
Primary: Respiratory Rate Accuracy Between the Respiratory Monitoring System and Manual Counting by a Trained Professional for the Supine Position — 22.9 Root Mean Squared…
Phase 1 N=13 A Study of Avacopan in Participants With Normal Renal Function and Participants With End-Stage Renal Disease (ESRD)
End-Stage Renal Disease (ESRD)
Primary: Maximum Observed Plasma Concentration (Cmax) of Avacopan — 105; 86.7; 108 nanograms per milliliter (ng/mL)